Strong Q1 delivery with raised FY27 guidance; margin timeline uncertain

₹228 Cr revenue, +90.7% YoY, aided by one-time inventory buildup from prior year

Q1 YoY 90.7% boosted by inventory effects; QoQ only 8.2%, normalized growth likely lower than Q1 but potentially 30-35%

Current EBIT margin ~9-10% (14.2% EBITDA margin); timeline repeatedly delayed; no concrete leverage yet visible

Q1 at ₹228 Cr; would need ₹144 Cr per remaining 3 quarters (annualized ₹912 Cr), suggests ₹800 Cr conservative

Requires 40-50% CAGR; multiple catalysts (cat food, Wagr, diagnostics) under development; base is small

Prior ₹570-580 Cr → now ₹800 Cr; ~38-40% increase. Management cautious wording ('around ₹800', won't commit to ₹1,000) but Q1 trajectory supports achievement

Prior guidance 20-25% annually → now 35-45% for new-age brands. Vintage business maintained at 15-20%, blended 30-35%

New initiatives (cat food, diagnostics, Wagr, OEM) added; targeting ₹100 Cr within 3 years from ₹40-45 Cr base at 40-50% growth

EBIT margin improvement to 12-13% pushed to 8-12 quarters; prior calls suggested 7-8 quarters, now extending further

New-age brands 35-45% YoY, vintage 15-20% YoY, blended 30-35% for next 3 years. Capacity expansion at Palghar + 43 new manufacturing locations will boost product line.

GX now in 19 states, ₹100-110 Cr base, very long way to go. Expect 25-35% growth YoY for next 5 years, have 3.5-4 year plan. Market huge; penetration very poor even in 2026.

Took over site last year; onboarded all brands; 1,500-2,000 medical products available. Pet parenting platform with breeders, trainers, groomers, vets, diagnostics, blood collection. Soft launch June 15, beta testing next 60-90 days.

₹30-40 Cr FY27, likely same next year. By Dec 2028/early 2029 aim to be largest manufacturing unit at single location. Maintenance CapEx ~2% of revenue at ₹1,000 Cr scale.

Q1 historically weaker (sales/import targets create last-quarter buying surge). This Q1 boost from prior-year inventory buildup and booking orders at lower prices. Expect similar growth going forward but at normalized 30-35% level.

Part of pet care; 42 variants in functional foods; Jain variant picked up very well in certain pockets. Normal biscuit range doing well in Tier 2/3/4 cities. Cat biscuits coming in next 6-7 months; on second/third mover position.

Currently ₹170-175 Cr (not high for size), 50% in cash. Will increase at ₹2,000-3,000 Cr revenue but in line with manufacturers. Positive cash flows expected to reduce external banking need.

Interest costs reducing; cash flows improving; using less credit limits. Credit rating improved BBB→BBB+. Interest as % of revenue drastically reduced. Overall factors combined.

Inventory days 140-135 currently, targeting 120; will hover 110-125 due to product mix. Rationalized 50% in last 2 years. 30-40% revenue growth adds only 10% inventory increase.

Pet care 45-55%, Mobility 40-50%, Nutrition 35-50%, Dermaceutics 70-75%. Blend improves bottom line. Focus on penetration over margin now. Within 8-11 quarters sudden profitability spike expected.

Never commit to such targets. Last year targeted ₹570 Cr, achieved ₹635 Cr. This year targeting ₹800 Cr, expect to cross it hopefully. ₹1,000 Cr I do not want to comment on; very anonymous kind of person.

Within 12 quarters should be near that number. Might do better, might take 1 quarter +/-. Business cycle not 90 days. Focused on long-term impact not margin timing.

Only company with nutraceuticals, diabetic formulations, functional foods, therapeutics, grooming, diagnostics. India's first diagnostics center in Mumbai; planning Malad and Vashi. Cat food Q3/Q4 launch; targeting ₹100 Cr within 3 years; 40-50% growth expected.

Every division has separate CEO with 10-25 years experience. India's #1 pet nutritionist on team. Very strong ops, finance, R&D teams. Lowest attrition in country; practically every core hire from 19 years ago still here. Well organized.

Q1 at ₹228 Cr suggests Q1 annualized run rate ₹912 Cr; ₹800 Cr conservative. Management on track, expect to cross, but cautious on ₹1,000 Cr

New-age brands 35-45%, vintage 15-20%. Supported by geographic expansion, new products (cat food, diagnostics, Wagr), and capacity additions

Small base, multiple catalysts (cat food Q3/Q4, Wagr, diagnostics, acquisitions), targeting ₹100 Cr in 3 years

Repeatedly deferred (7-8 quarters → 8-11 quarters → 12 quarters); no clear evidence of leverage yet; NPM at 5.8% with modest improvement trajectory

Mechanism is geographic demographic completion then channel penetration; requires normalized growth to sustain; timing vague

Maintenance CapEx ~2% at ₹1,000 Cr revenue scale; Goal: largest single-location facility by Dec 2028/early 2029; already added 43 locations

Wagr platform still in beta (soft launched June 15), cat food launching Q3/Q4, diagnostics centers ramping (Mumbai, Malad, Vashi), acquisitions pending. Multiple concurrent execution risks.

EBIT margin target 12-13% repeatedly deferred (originally 7-8 quarters, now 8-12 quarters). Currently at 9-10% EBIT, 5.8% NPM. No clear evidence of operational leverage yet materializing.

Q1's 90.7% YoY growth partially driven by one-time inventory buildup from prior year and locked-in lower customer pricing. Normalized growth expected 30-35%, which is still strong but materially lower.

Inventory days at 140-135, well above pharma norm. Target 120 but management expects 110-125 minimum due to 2,100 SKUs and product mix. Ties up cash flow.

Pet care, mobility, nutrition products entering competitive segments dominated by larger players (ITC, MNCs). Pricing power and customer acquisition costs may compress margins.